Advisors Capital Management LLC Boosts Stock Holdings in AbbVie Inc. $ABBV

Advisors Capital Management LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.9% in the third quarter, Holdings Channel.com reports. The firm owned 614,095 shares of the company’s stock after acquiring an additional 22,999 shares during the period. AbbVie makes up about 1.8% of Advisors Capital Management LLC’s investment portfolio, making the stock its 5th largest position. Advisors Capital Management LLC’s holdings in AbbVie were worth $142,188,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Evolution Wealth Management Inc. bought a new stake in AbbVie in the 2nd quarter valued at approximately $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie in the second quarter valued at approximately $36,000. Delos Wealth Advisors LLC acquired a new position in AbbVie during the second quarter worth $39,000. Finally, Abich Financial Wealth Management LLC bought a new position in AbbVie in the third quarter valued at $49,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 0.5%

ABBV opened at $232.69 on Wednesday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The business has a 50 day moving average of $223.93 and a 200-day moving average of $221.63. The stock has a market cap of $411.25 billion, a price-to-earnings ratio of 98.60, a PEG ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the business earned $2.16 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Scotiabank initiated coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research report on Tuesday, November 4th. Piper Sandler reissued an “overweight” rating and set a $299.00 price target on shares of AbbVie in a research report on Wednesday. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Finally, JPMorgan Chase & Co. upped their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.56.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.